CD274 and osteosarcoma: Clinical trials evaluating PD-1 inhibitors (e.g., pembrolizumab, nivolumab) and PD-L1 inhibitors (e.g., atezolizumab, durvalumab) in osteosarcoma patients have demonstrated mixed outcomes.